Synthesis and evaluation of peptidic metal chelators for neuroprotection in neurodegenerative diseases

Journal of Peptide Research

Volumn 66, Issue 4, 2005, Pages 190-203

  Zheng, H ^a   Youdim, M B H ^b   Weiner, L M ^a   Fridkin, M ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Antioxidant; Iron chelator; Neurodegenerative diseases; Neuropeptide; Neuroprotection

Indexed keywords

HYDROXYL RADICAL; IRON CHELATE; METAL CHELATE; NEUROPEPTIDE; OXIDOPAMINE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ARTICLE; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CHELATION; DEGENERATIVE DISEASE; ELECTRON SPIN RESONANCE; FRIEDREICH ATAXIA; HUNTINGTON CHOREA; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; RAT;

ANIMALS; CHELATING AGENTS; FREE RADICAL SCAVENGERS; METALS, HEAVY; NEURODEGENERATIVE DISEASES; NEUROPEPTIDES; PC12 CELLS; RATS;

EID: 25144525554     PISSN: 1397002X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3011.2005.00289.x     Document Type: Article

References (40)

1. Gozes, I., Bardea, A., Bechar, M., Pearl, O., Reshef, A., Zamostiano, R., Davidson, A., Rubinraut, S., Giladi, E., Fridkin, M. & Brenneman, D.E. (1997) Neuropeptides and neuronal survival: neuroprotective strategy for Alzheimer's disease. Ann. N. Y. Acad. Sci. 814, 161-166.
2. Offen, D., Sherki, Y., Melamed, E., Fridkin, M., Brenneman, D.E. & Gozes, I. (2000) Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res. 854, 257-262.
3. Gozes, I., Lilling, G., Glazer, R., Ticher, A., Ashkenazi, I.E., Davidson, A., Rubinraut, S., Fridkin, M. & Brenneman, D.E. (1995) Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J. Pharmacol. Exp. Ther. 273, 161-167.
4. Gozes, I., Perl, O., Giladi, E., Davidson, A., Ashur-Fabian, O., Rubinraut, S. & Fridkin, M. (1999) Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design. Proc. Natl Acad. Sci. U S A 96, 4143-4148.
5. Hasenohrl, R.U., De Souza-Silva, M.A., Nikolaus, S., Tomaz, C., Brandao, M.L., Schwarting, R.K.W. & Huston, J.P. (2000) Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery. Neuropeptides (Edinburgh) 34, 272-280.
6. Moosmann, B. & Behl, C. (2002) Secretory peptide hormones are biochemical antioxidants: structure-activity relationship. Mol. Pharmacol. 61, 260-268.
7. Kochman, K., Gajewska, A., Kochman, H., Kozlowski, H., Masiukiewicz, E. & Rzeszotarska, B. (1997) Binding of Cu2+, Zn2+, and Ni2+-GnRH complexes with the rat pituitary receptor. J. Inorg. Biochem. 65, 277-282.
8. D'Amelio, N., Gaggelli, E., Gajewska, A., Kochman, H., Kochman, K., Kozlowski, H., Latajka, Z., Mlynarz, P., Panek, J. & Valensin, G. (2003) Structural analysis and sheep pituitary receptor binding of GnRH and its complexes with metal ions. J. Inorg. Biochem. 94, 28-35.
9. Hayashi, T. & Su, T.-P. (2003) Chronic [D-Ala2, D-Leu5]enkephalin treatment increases the nerve growth factor in adult mouse brain. Eur. J. Pharmacol. 464, 237-239.
10. Mandel, S., Grunblatt, E., Riederer, P., Gerlach, M., Levites, Y. & Youdim, M.B.H. (2003) Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drugs 17, 729-762.
11. Ben-Shachar, D., Nava Kahana, N., Kampel, V., Warshawsky, A. & Youdim, M. (2004) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology 46, 254-263.
12. Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J.Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M.F., DiMonte, D., Volitaskis, I., Ellerby, L., Cherny, R.A., Ashley, I., Bush, A.I. & Andersen, J.K. (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37, 899-909.
13. Youdim, M.B.H., Stephenson, G. & Ben Shachar, D. (2004) Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann. N. Y. Acad. Sci. 1012, 306-325.
14. Zecca, L., Youdim, M.B.H., Riederer, P., James, R., Connor, J.R. & Crichton, R.R. (2004) Iron, brain aging and neurodegerative disorders. Nat. Rev. Neurosci. 5, 863-873.
15. Gassen, M., Glinka, Y., Pinchasi, B. & Youdim, M.B.H. (1996) Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur. J. Pharmacol. 308, 219-225.
16. Warshawsky, A., Youdim, M., Fridkin, M., Zheng, H.L. & Warshawsky, R. (2004) Preparation of Neuroprotective Iron Chelators and Pharmaceutical Compositions Comprising them. International Publication Number WO 2004041151 A2.
17. Yahalom, D., Koch, Y., Ben-Aroya, N. & Fridkin, M. (1999) Synthesis and bioactivity of fatty acid-conjugated GnRH derivatives. Life Sci. 64, 1543-1552.
18. Yahalom, D., Rahimipour, S., Koch, Y., Ben-Aroya, N. & Fridkin, M. (2000) Structure-activity studies of reduced-size gonadotropin releasing hormone agonists derived from the sequence of an endothelin antagonist. J. Med. Chem. 43, 2824-2830.
19. Daane, T.A. & Parlow, A.F. (1971) Periovulatory patterns of rat serum follicle stimulating hormone and luteinizing hormone during the normal estrous cycle: effects of pentobarbital. Endocrinology 88, 653-667.
20. Desbuquois, B. & Aurbach, G.D. (1971) Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays. J. Clin. Endocrinol. Metab. 33, 732-738.
21. Pardridge, W.M. (1991) Peptide Drug Delivery to the Brain. Raven Press, Ltd, New York, USA.
22. Kayyali, R., Pannala, A.S., Khodr, H. & Hider Robert, C. (1998) Comparative radical scavenging ability of bidentate iron(III) chelators. Biochem. Pharmacol. 55, 1327-1332.
23. Turnquist, T.D. & Sandell, E.B. (1968) Stability constants of iron(III)-8-hydroxylquinoline complexes. Anal. Chim. Acta 42, 239-245.
24. Frederickson, C.J., Kasarskis, E.J., Ringo, D. & Frederickson, R.E. (1987) Qinoline fluorescence method for visualizing and assaying the histochemically reactive zinc (bouton zinc) in the brain. J. Neurosci. Methods 20, 91-103.
25. Pratico, D. & Sung, S. (2004) Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. J. Alzheimers Dis. 6, 171-175.
26. MacCarthy, P. (1978) Simplified experimental route for obtaining Job's curves. Anal. Chem. 50, 2165.
27. Gilgun-Sherki, Y., Melamed, E. & Offen, D. (2001) Oxidative stress induced neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 40, 959-975.
28. Rahimipour, S., Ben-Aroya, N., Ziv, K., Chen, A., Fridkin, M. & Koch, Y. (2003) Receptor-mediated targeting of a photosensitizer by its conjugation to gonadotropin-releasing hormone analogues. J. Med. Chem. 46, 3965-3974.
29. Walkinshaw, G. & Waters, C.M. (1994) Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of apoptosis. Neuroscience 63, 975-987.
30. Grunblatt, E., Mandel, S. & Youdim, M.B.H. (2000) Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP. Ann. N. Y. Acad. Sci. 899, 262-273.
31. Rukenstein, A., Rydel, R.E. & Greene, L.A. (1991) Multiple agents rescue PC12 cells from serum-free cell death by translation-and transcription-independent mechanisms. J. Neurosci. 11, 2552-2563.
32. Greene, L.A. (1978) Nerve growth factor prevents the death and stimulates the neuronal differentiation of clonal PC 12 pheochromocytoma cells in serum-free medium. J. Cell Biol. 78, 747-755.
33. Youdim, M.B.H. & Weinstock, M. (2002) Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline. Mech. Ageing Dev. 123, 1081-1086.
34. Glinka, Y., Gassen, M. & Youdim, M.B.H. (1997) Mechanism of 6-hydroxy-dopamine neurotoxicity. J. Neural Transm. Suppl. 5, 55-66.
35. Soto-Otero, R., Mendez-Alvarez, E., Hermida-Ameijeiras, A., Munoz-Patino, A.M. & Labandeira-Garcia, J.L. (2000) Autoxidation and neurotoxicity of 6-hydroxy-dopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J. Neurochem. 74, 1605-1612.
36. Atabay, C., Cagnoli, C.M., Kharlamov, E., Ikonomovic, M.D. & Manev, H. (1996) Removal of serum from primary cultures of cerebellar granule neurons induces oxidative stress and DNA fragmentation: protection with antioxidants and glutamate receptor antagonists. J. Neurosci. Res. 43, 465-475.
37. Lallemend, F., Lefebvre, P.P., Hans, G., Rigo, J.M., Van De Water, T.R., Moonen, G. & Malgrange, B. (2003) Substance P protects spiral ganglion neurons from apoptosis via PKC-Ca2+-MAPK/ERK pathways. J. Neurochem. 87, 508-521.
38. Przedborski, S. & Jackson-Lewis, V.R. (2000) ROS and Parkinson's disease: a view to a kill. Oxidative Stress Dis. 5, 273-290.
39. Weiner, L.M. (1995) Quantitative determination of thiol groups in low and high molecular weight compounds by electron paramagnetic resonance. Methods Enzymol. 251, 87-105.
40. 2 radicals with nitrones in the ultraviolet photolysis of aqueous hydrogen peroxide solutions. Can. J. Chem. 52, 3549-3553.